In Phase A, members will acquire distinctive doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Added contributors is going to be enrolled at the recognized monotherapy dosign routine. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 is going to be specified as "increase-on" therapy. https://abbv-744inclinicaltrialsf80234.bcbloggers.com/31416827/details-fiction-and-abbv-744-in-acute-myeloid-leukemia-aml